In our experience, evaluating multiple tumor-specific analytes, such as D-2-HG and IDH1 VAF, can provide a “reality check” on the performance of each biomarker in real time, particularly when results are concordant.54 When results differ, further investigation is required to understand the discrepancies. Here, IDH1 is linked to neoplasm.